Found 5 matching trials
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies PHASE2 Background:
\- The current standard of care for advanced lung cancer and c...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) PHASE1 This study is being conducted to determine if a combination of AZD6244 give...
Show More Learn More & Join Trial
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2 Background:
AZD6244 (ARRY-142886) is an investigational anticancer drug th...
Show More Location
University of California, Davis
Learn More & Join Trial
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer PHASE2 Different people have different biomarkers (chemical "markers" in the blood...
Show More Learn More & Join Trial
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer PHASE2 This phase II trial studies how well giving selumetinib and erlotinib hydro...
Show More Learn More & Join Trial